+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Spinal Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • PDF Icon

    Report

  • 134 Pages
  • May 2024
  • Region: Global
  • IMARC Group
  • ID: 5969972
The 7 major spinal disorders markets reached a value of US$ 5.1 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 7.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.74% during 2023-2034.

The spinal disorders market has been comprehensively analyzed in this report titled "Spinal Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Spinal disorders refer to a broad array of conditions that affect the structures and functions of the spine. Some of the common symptoms associated with the ailments include localized or radiating pain, stiffness, reduced range of motion in the affected area of the spine, etc. In addition to this, nerve compression or irritation may cause tingling or weakness in the back, neck, or extremities. Many spinal disorders can also lead to postural abnormalities, such as curvature of the spine or an exaggerated hunchback posture. Depending on the specific condition, additional symptoms may include difficulty walking, muscle spasms, bowel or bladder dysfunction, paralysis, etc. The diagnosis of spinal disorders involves a comprehensive evaluation by healthcare professionals, typically orthopedic specialists, neurologists, or spine specialists. The diagnostic process may consist of a detailed medical history, a physical examination, and several imaging procedures, like X-rays, MRI scans, CT scans, etc., to assess the structure and condition of the spine. Various additional tests, such as electromyography (EMG) and nerve conduction studies, may be conducted to evaluate nerve function. Furthermore, blood tests and numerous other laboratory investigations can help to identify underlying causes or rule out certain conditions.

The increasing incidences of congenital or developmental abnormalities of the spine that can cause spinal instability, deformities, or nerve compression are primarily driving the spinal disorders market. Furthermore, the rising prevalence of several associated risk factors, such as degenerative changes, traumatic events like falls and motor vehicle accidents, prolonged poor posture, improper body mechanics, spinal infections, etc., is creating a positive outlook for the market. Apart from this, the widespread adoption of facet joint injections, nerve blocks, and epidural steroid injections for providing temporary pain relief and reducing inflammation in specific areas of the spine is also bolstering the market growth. Moreover, the emerging popularity of minimally invasive techniques, such as percutaneous discectomy and vertebroplasty/kyphoplasty, since they involve smaller incisions, minimal tissue disruption, and shorter recovery times compared to traditional open surgery, is acting as another significant growth-inducing factor. Additionally, the escalating utilization of novel interventions, including platelet-rich plasma (PRP) injections and stem cell therapy, to promote tissue healing and stimulate tissue regeneration is expected to drive the spinal disorders market during the forecast period.

This report provides an exhaustive analysis of the spinal disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for spinal disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the spinal disorders market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the spinal disorders market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the spinal disorders market

Competitive Landscape:

This report also provides a detailed analysis of the current spinal disorders marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the spinal disorders market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the spinal disorders market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the spinal disorders market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of prevalent cases (​2018-2034​) of spinal disorders across the seven major markets?
  • What is the number of prevalent cases (​2018-2034​) of spinal disorders by age across the seven major markets?
  • What is the number of prevalent cases (​2018-2034​) of spinal disorders by gender across the seven major markets?
  • How many patients are diagnosed (​2018-2034​) with spinal disorders across the seven major markets?
  • What is the size of the spinal disorders patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of spinal disorders?
  • What will be the growth rate of patients across the seven major markets?

Spinal Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for spinal disorders drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the spinal disorders market?
  • What are the key regulatory events related to the spinal disorders market?
  • What is the structure of clinical trial landscape by status related to the spinal disorders market?
  • What is the structure of clinical trial landscape by phase related to the spinal disorders market?
  • What is the structure of clinical trial landscape by route of administration related to the spinal disorders market?
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Spinal Disorders - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Spinal Disorders - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Spinal Disorders - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 Spinal Disorders - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Spinal Disorders - Unmet Needs10 Spinal Disorders - Key Endpoints of Treatment
11 Spinal Disorders - Marketed Products
11.1 List of Spinal Disorders Marketed Drugs Across the Top 7 Markets
11.1.1 Lyrica (Pregabalin)- Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Spinraza (Nusinersen)- Biogen
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Evrysdi (Risdiplam)- Genentech
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Zolgensma (Onasemnogene Abeparvovec-Xioi)- Novartis Gene Therapies
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 Spinal Disorders - Pipeline Drugs
12.1 List of Spinal Disorders Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. Spinal Disorders - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Spinal Disorders - Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Spinal Disorders - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Spinal Disorders - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Spinal Disorders - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Spinal Disorders - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Spinal Disorders - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Spinal Disorders - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Spinal Disorders - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Spinal Disorders - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Spinal Disorders - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Spinal Disorders - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Spinal Disorders - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Spinal Disorders - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Spinal Disorders - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Spinal Disorders - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Spinal Disorders - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Spinal Disorders - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Spinal Disorders - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Spinal Disorders - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Spinal Disorders - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Spinal Disorders - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Spinal Disorders - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Spinal Disorders - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Spinal Disorders - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Spinal Disorders - Access and Reimbursement Overview
16 Spinal Disorders - Recent Events and Inputs From Key Opinion Leaders
17 Spinal Disorders Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Spinal Disorders Market - Strategic Recommendations19 Appendix

Methodology

Loading
LOADING...

Table Information